finally, a company that says yes -
Americans can live free from cigarettes and vape devices. We are not against your choice to smoke or vape; we are against leaving people without support. In a country built on freedom and informed decision making, Redwood is committed to delivering evidence based solutions that contribute to a stronger and healthier America.
What We Do
Redwood Scientific Technologies
Redwood Scientific Technologies, Inc. is a life sciences company focused on the development and commercialization of nicotine free cessation solutions delivered through proprietary oral thin film technology. Our core products, TBX Free and TBX Vape Free, are designed to support individuals seeking to overcome nicotine dependence from traditional cigarettes and vape devices. By combining pharmaceutical grade formulation with an innovative sublingual delivery system, we aim to provide a fast acting, convenient and scalable alternative within a multi billion dollar global cessation market.
Upon completion of our planned randomized, double blind, placebo controlled clinical effectiveness studies, the Company intends to commercialize TBX Free and TBX Vape Free directly into the wholesale and retail market pursuant to the regulatory framework applicable to homeopathic over the counter drug products under the Federal Food, Drug, and Cosmetic Act and related guidance. Based on current regulatory interpretation and counsel review, no additional pre market approval is required beyond proper establishment registration, product listing, compliant labeling and adherence to applicable manufacturing standards. This regulatory pathway is intended to allow immediate market entry following successful study completion, subject to ongoing compliance with applicable federal and state laws.
Core Technology
Redwood Thin Film Biotech Platform
Redwood’s platform is built on a proprietary oral thin film delivery system engineered for rapid sublingual absorption. Each strip is precisely formulated to dissolve within seconds, delivering a consistent dose of active ingredient without the need for water, inhalation, or combustion.
Unlike traditional nicotine replacement formats such as gum, patches, or lozenges, the thin film format is discreet, portable, and designed for ease of compliance. The technology allows for controlled ingredient dispersion, scalable manufacturing, and adaptability across multiple formulations, positioning Redwood to address nicotine dependence through a modern, evidence based delivery platform.
Our Milestone
Research and Development Initiated for Redwood Oral Thin Film Strips
The Company began research and development efforts focused on proprietary oral thin film strip technology designed for nicotine cessation and other health related applications.
TBX Free Achieves Nationwide Distribution
TBX Free was commercially distributed across the United States, establishing early brand recognition and validating consumer demand within the nicotine cessation category.
Company Subsidiary Manufactures Oral Thin Film Strips in California
A Company subsidiary established domestic manufacturing operations in California for the production of oral thin film strips, strengthening supply chain control and supporting United States based production capabilities.
Company Founder Establishes Largest Made in the USA 3 Ply Mask Manufacturing Facility
During the global health crisis, the Company’s founder led the development and buildout of one of the largest domestically produced 3 ply surgical mask manufacturing operations in the United States, demonstrating operational execution at scale and commitment to domestic production.
Company Develops Full Line of TBX Vape Free Products to Address the Vape Crisis
Redwood Scientific Technologies expanded its product platform to include a full line of TBX Vape Free formulations designed specifically to support individuals seeking to discontinue vape device use, addressing the growing national concern surrounding youth and adult vaping.
Federal Court Returns Company to Operations
Following the conclusion of federal proceedings and the dissolution of the receivership, the Company was formally returned to operations, allowing Redwood Scientific Technologies to resume strategic development, regulatory compliance initiatives, and preparation for clinical effectiveness studies and commercialization.